Dr. Nadim Nasr

So I joined the practice here in 2010, so I've been here for 14 years now. We started out as a small practice of two radiation oncologists. We've now, over the last 14 years, expanded to two centers. They're both hospital-based, community hospital-based, and there's four of us in the group.

So I joined the practice here in 2010, so I've been here for 14 years now. We started out as a small practice of two radiation oncologists. We've now, over the last 14 years, expanded to two centers. They're both hospital-based, community hospital-based, and there's four of us in the group.

So I joined the practice here in 2010, so I've been here for 14 years now. We started out as a small practice of two radiation oncologists. We've now, over the last 14 years, expanded to two centers. They're both hospital-based, community hospital-based, and there's four of us in the group.

I am the one that does the vast majority of the prostate cancers in the group, but I do treat really everything else. We have the full gamut of options for treatment, including external beam, brachytherapy, and SBRT. A significant portion of my training at Georgetown was in SBRT, and so I've got a lot of experience in treating SBRT, especially for prostate cancer.

I am the one that does the vast majority of the prostate cancers in the group, but I do treat really everything else. We have the full gamut of options for treatment, including external beam, brachytherapy, and SBRT. A significant portion of my training at Georgetown was in SBRT, and so I've got a lot of experience in treating SBRT, especially for prostate cancer.

I am the one that does the vast majority of the prostate cancers in the group, but I do treat really everything else. We have the full gamut of options for treatment, including external beam, brachytherapy, and SBRT. A significant portion of my training at Georgetown was in SBRT, and so I've got a lot of experience in treating SBRT, especially for prostate cancer.

I think there is. And the main reason is that if you look at the changes in the NCCN guidelines, especially over the last four or five years, what you're seeing is a lot more inclusion of SBRT as opposed to IMRT in the treatment of prostate cancer. And with SBRT, you are using such higher doses per treatment that it's really important to try to spare that anterior rectal wall.

I think there is. And the main reason is that if you look at the changes in the NCCN guidelines, especially over the last four or five years, what you're seeing is a lot more inclusion of SBRT as opposed to IMRT in the treatment of prostate cancer. And with SBRT, you are using such higher doses per treatment that it's really important to try to spare that anterior rectal wall.

I think there is. And the main reason is that if you look at the changes in the NCCN guidelines, especially over the last four or five years, what you're seeing is a lot more inclusion of SBRT as opposed to IMRT in the treatment of prostate cancer. And with SBRT, you are using such higher doses per treatment that it's really important to try to spare that anterior rectal wall.

And now with the use of PSMA PET scans to further narrow down which patients are good candidates for prostate-directed therapy, we're really doing more and more of that. And I think that there is really a large need for perirectal spacing in the majority, but not all patients.

And now with the use of PSMA PET scans to further narrow down which patients are good candidates for prostate-directed therapy, we're really doing more and more of that. And I think that there is really a large need for perirectal spacing in the majority, but not all patients.

And now with the use of PSMA PET scans to further narrow down which patients are good candidates for prostate-directed therapy, we're really doing more and more of that. And I think that there is really a large need for perirectal spacing in the majority, but not all patients.

Well, I want to agree with Eric. I think that we've mostly moved away from standard fractionation for prostate cancer. If you look at radiobiologic studies, what they actually show is that most prostate cancers respond a lot better to higher doses per treatment. And so I think we're going to see a significant move towards hyperfractionation in almost, you know, most of these cancers.

Well, I want to agree with Eric. I think that we've mostly moved away from standard fractionation for prostate cancer. If you look at radiobiologic studies, what they actually show is that most prostate cancers respond a lot better to higher doses per treatment. And so I think we're going to see a significant move towards hyperfractionation in almost, you know, most of these cancers.

Well, I want to agree with Eric. I think that we've mostly moved away from standard fractionation for prostate cancer. If you look at radiobiologic studies, what they actually show is that most prostate cancers respond a lot better to higher doses per treatment. And so I think we're going to see a significant move towards hyperfractionation in almost, you know, most of these cancers.

And again, in my own practice, I can't remember the last time I treated a prostate in nine weeks. Most of my prostates, even the IMRT, are done in the five and a half to six week courses of treatment. And again, in those cases, having a spacer in place really does cut down that docety into your rectal wall.

And again, in my own practice, I can't remember the last time I treated a prostate in nine weeks. Most of my prostates, even the IMRT, are done in the five and a half to six week courses of treatment. And again, in those cases, having a spacer in place really does cut down that docety into your rectal wall.

And again, in my own practice, I can't remember the last time I treated a prostate in nine weeks. Most of my prostates, even the IMRT, are done in the five and a half to six week courses of treatment. And again, in those cases, having a spacer in place really does cut down that docety into your rectal wall.

The only patients that I do hesitate in placing them, and I place my own spacers and fiducials. It's not our urologists that do them. The only patients that I hesitate in are the patients where we suspect some extension outside the prostate on the MRIs that they had before the biopsies. Those are the ones that I do hesitate in putting in spacers.

The only patients that I do hesitate in placing them, and I place my own spacers and fiducials. It's not our urologists that do them. The only patients that I hesitate in are the patients where we suspect some extension outside the prostate on the MRIs that they had before the biopsies. Those are the ones that I do hesitate in putting in spacers.